Antianginal and antihypertensive equipoise activity. Inhibits the flow of calcium ions into cardiac myocytes and vascular smooth muscle cells. It relaxes smooth muscles of coronary and peripheral arteries. Expanding peripheral vessels, reducing peripheral resistance and afterload on the heart. Increase coronary blood flow, reducing myocardial oxygen demand. When taken twice daily Kaltsigard equipoise Retard provides control high blood pressure for 24 hours. Kaltsigard Retard lowers blood pressure so that its percentage decrease is directly related to the original value. In patients with normal blood pressure Kaltsigard Retard generally has little or no effect on blood pressure.
After oral administration Kaltsigard equipoise Retard completely absorbed from the gastrointestinal tract. After a single dose of the drug is gradually controlled by increasing its concentration in blood plasma, which is retained with slight variations to the next through the drug 12 hours. Almost completely metabolized in the liver to inactive metabolites. 60% -80% of nifedipine as metabolites excreted in urine. The half-life is approximately 2 hours. Less than 0.1% of the drug found in the urine unchanged rest excreted in the feces as metabolites. The pharmacokinetics of the drug may vary in patients with chronic liver disease.
Hypersensitivity to nifedipine, a equipoise dihydropyridine derivative other or to other components of the formulation; hypotension, cardiogenic shock, collapse, marked aortic stenosis, sick sinus syndrome, angina unstable, severe heart failure, acute phase of myocardial infarction (during the first 4 weeks), pregnancy, lactation.
Caution should be exercised when administering the drug Kaltsigard Retard in patients with arterial hypertension, heart failure decompensation, impaired liver and kidney function. A small percentage of patients have chest pain after 30-60 min after administration Kaltsigarda Retard. Although the effect of “steal” has not been found, patients who experience increased angina symptoms should discontinue treatment Kaltsigardom Retard. For patients with diabetes dose should be individualized diabetes.
Not recommended for use in children under 18 years. When you remove the drug dose is reduced gradually in order to prevent the development of “withdrawal syndrome”. During treatment should refrain from drinking alcohol. With care prescribe a drug transport drivers and other occupations that require rapid psychomotor reactions.
Dosing and Administration
Dosage is determined individually. The average dose is 1 tablet (20 mg) twice a day with a small amount of liquid during or after a meal. In case of insufficient clinical response to gradually increasing the dose. The maximum dose is 40 mg twice daily.
Since the cardiovascular system: possible – facial flushing, feeling of fever, tachycardia, peripheral edema, hypotension.
in some patients, especially at the equipoise beginning of treatment, angina pectoris attacks may occur, which requires discontinuation of the drug, the part of the central nervous system: headache, dizziness, fatigue, drowsiness. When using high doses of the drug are marked individual cases of paresthesia of limbs, tremor, disorders of the lungs, sleep disturbance, the part of the gastrointestinal tract and liver: nausea, constipation, diarrhea. Chronic administration of the drug cases increased activity of “liver” transaminases in blood serum can be observed occurrence of intrahepatic cholestasis; Hematopoietic system:rarely – reversible thrombocytopenia, leukopenia, anemia, From the urinary system: an increase in daily urine; in patients with renal insufficiency – renal impairment; Allergic reactions: seldom – rash, itchy skin; Other: long-term use – myalgia, gynecomastia, gingival hyperplasia, hyperglycemia.
Interaction with other drugs
In an application Kaltsigarda and Retard:
- beta-blockers, other antihypertensive drugs, tricyclic antidepressants, diuretics, vasodilators – enhanced hypotensive effect of the drug;
- in combination with nitrates observed tachycardia and increased hypotensive effect; diltiazem – the clearance of nifedipine is reduced. By using such a combination is necessary to reduce the dose Kaltsigarda Retard and carefully monitor the patient;
- antiarrhythmic drugs (eg amiodarone and quinidine) – can amplify their negative inotropic effect;
- digoxin reduced clearance of digoxin, increases level of digoxin in plasma and the risk of developing digoksinovoy intoxication. In these cases it is necessary to reduce the dose of digoxin and check its level in blood plasma;
- theophylline may increase plasma theophylline levels that require dose correction;
- cimetidine and, to a lesser extent, ranitidine may increase the plasma level of nifedipine and intensify its action;
- vincristine difficult removal of the last of the body, which increases the risk of increasing the side effects of vincristine;
- cephalosporins increased bioavailability of cephalosporins.
Symptoms: severe hypotension, cardiac arrhythmias (bradycardia or tachycardia). With an increase in the phenomena of intoxication can occur hypoxia, cardiogenic shock, impaired consciousness.Treatment : gastric lavage, activated charcoal, intravenous administration of calcium salts. Treatment is symptomatic. Hemodialysis is not effective.
10 tablets in a blister made ??of PVC film and aluminum foil. 3 blisters or 10 blisters with instruction for use in a cardboard box.
The sample is not for sale: 4 tablets or 10 tablets in a blister made ??of PVC film and aluminum foil. 1 blister with instruction on use is packed in a cardboard box.
Store at temperatures below 30 ° C, protected from light and moisture.
Keep out of reach of children
Shelf life :. 3 years from date of manufacture
Do not use after the date printed on the packaging.
Conditions of supply of pharmacies : Prescription nandrolone fenilpropionato